On 3rd November, Servier announced the Phase 3 GRAND CANYON clinical trial of sevasemten in people living with Becker muscular dystrophy (BMD) did not meet its primary endpoint which means the trial did not demonstrate a statistically significant benefit on the North Star Ambulatory Assessment (NSAA) compared with placebo. The study’s secondary endpoints were also not met.
The GRAND CANYON study was a global, placebo-controlled trial that followed participants for 18 months to evaluate the effectiveness and safety of sevasemten in BMD. According to Servier, the findings from GRAND CANYON were not consistent with some of the results seen in earlier clinical studies, including the Phase 2 CANYON study. The company is now carrying out a detailed analysis of the trial data, alongside results from previous studies, to better understand these findings.
You can read Servier’s update here.
If you have any questions or concerns about your treatment, please speak with your specialist Duchenne care team. If you would like a wider conversation following this news, please give us a call on 07535 498 506 or email us at support@actionduchenne.org. If you have any questions about the science, research, or the information shared in this update, please feel free to contact our Science Team at science@actionduchenne.org, who will be happy to support you.
We recognise that treatment updates can sometimes feel worrying. If you have concerns, your specialist clinical team remains the best source of advice for your individual circumstances.
Givinostat (Duvyzat®): MHRA Shares Interim Monitoring Advice 
